|
1
|
Feichtinger M and Rodriguez-Wallberg KA:
Fertility preservation in women with cervical, endometrial or
ovarian cancers. Gynecol Oncol Res Pract. 3:82016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Y and Xu C: Human
papillomavirus-related cancers. Adv Exp Med Biol. 1018:23–34. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Serrano B, Brotons M, Bosch FX and Bruni
L: Epidemiology and burden of HPV-related disease. Best Pract Res
Clin Obstet Gynaecol. 47:14–26. 2018. View Article : Google Scholar
|
|
4
|
Pappa KI, Kontostathi G, Lygirou V,
Zoidakis J and Anagnou NP: Novel structural approaches concerning
HPV proteins: Insight into targeted therapies for cervical cancer
(Review). Oncol Rep. 39:1547–1554. 2018.PubMed/NCBI
|
|
5
|
Willows K, Lennox G and Covens A:
Fertility-sparing management in cervical cancer: Balancing
oncologic outcomes with reproductive success. Gynecol Oncol Res
Pract. 3:92016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parkin DM: Cancer in developing countries.
Cancer Surv. 19-20:519–561. 1994.PubMed/NCBI
|
|
7
|
Bentivegna E, Maulard A, Pautier P,
Chargari C, Gouy S and Morice P: Fertility results and pregnancy
outcomes after conservative treatment of cervical cancer: A
systematic review of the literature. Fertil Steril. 106:1195–1211
e1195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawrenz B, Mahajan N and Fatemi HM: The
effects of cancer therapy on women’s fertility: What do we know
now? . Future Oncol. 12:1721–1729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barra F, Lorusso D, Leone Roberti,
Maggiore U, Ditto A, Bogani G, Raspagliesi F and Ferrero S:
Investigational drugs for the treatment of cervical cancer. Expert
Opin Investig Drugs. 26:389–402. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hampson L, Martin-Hirsch P and Hampson IN:
An overview of early investigational drugs for the treatment of
human papilloma virus infection and associated dysplasia. Expert
Opin Investig Drugs. 24:1529–1537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell MT, Siefker-Radtke AO and Gao J:
The state of immune checkpoint inhibition in urothelial carcinoma:
Current evidence and future areas of exploration. Cancer J.
22:96–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mermelekas G and Zoidakis J: Mass
spectrometry-based membrane proteomics in cancer biomarker
discovery. Expert Rev Mol Diagn. 14:549–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomonaga T and Kume H: Biomarker discovery
of colorectal cancer using membrane proteins extracted from cancer
tissues. Rinsho Byori. 63:322–327. 2015.Japanese. PubMed/NCBI
|
|
14
|
Pappa KI, Lygirou V, Kontostathi G,
Zoidakis J, Makridakis M, Vougas K, Daskalakis G, Polyzos A and
Anagnou NP: Proteomic analysis of normal and cancer cervical cell
lines reveals deregulation of cytoskeleton-associated proteins.
Cancer Genomics Proteomics. 14:253–266. 2017. View Article : Google Scholar :
|
|
15
|
Kontostathi G, Zoidakis J, Makridakis M,
Lygirou V, Mermelekas G, Papadopoulos T, Vougas K, Vlamis-Gardikas
A, Drakakis P, Loutradis D, et al: Cervical cancer cell line
secretome highlights the roles of transforming growth
factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on
cervical carcinogenesis. Biomed Res Int. 2017:41807032017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pappa KI, Kontostathi G, Makridakis M,
Lygirou V, Zoidakis J, Daskalakis G and Anagnou NP: High resolution
proteomic analysis of the cervical cancer cell lines secretome
documents deregulation of multiple proteases. Cancer Genomics
Proteomics. 14:507–521. 2017.PubMed/NCBI
|
|
17
|
Makridakis M, Gagos S, Petrolekas A,
Roubelakis MG, Bitsika V, Stravodimos K, Pavlakis K, Anagnou NP,
Coleman J and Vlahou A: Chromosomal and proteome analysis of a new
T24-based cell line model for aggressive bladder cancer.
Proteomics. 9:287–298. 2009. View Article : Google Scholar
|
|
18
|
Narisawa-Saito M, Handa K, Yugawa T, Ohno
S, Fujita M and Kiyono T: HPV16 E6-mediated stabilization of ErbB2
in neoplastic transformation of human cervical keratinocytes.
Oncogene. 26:2988–2996. 2007. View Article : Google Scholar
|
|
19
|
Eng JK, Fischer B, Grossmann J and Maccoss
MJ: A fast SEQUEST cross correlation algorithm. J Proteome Res.
7:4598–4602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Apostolou P, Toloudi M and Papasotiriou I:
Identification of genes involved in breast cancer and breast cancer
stem cells. Breast Cancer (Dove Med Press). 7:183–191. 2015.
|
|
21
|
Holden S and Raymond FL: The human gene
CXorf17 encodes a member of a novel family of putative
transmembrane proteins: cDNA cloning and characterization of
CXorf17 and its mouse ortholog orf34. Gene. 318:149–161. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartolomé RA, García-Palmero I, Torres S,
López-Lucendo M, Balyasnikova IV and Casal JI: IL13 Receptor α2
signaling requires a scaffold protein, FAM120A, to activate the FAK
and PI3K pathways in colon cancer metastasis. Cancer Res.
75:2434–2444. 2015. View Article : Google Scholar
|
|
23
|
Zang Y, Nie W, Fang Z and Li B: Cleft lip
and palate transmembrane protein 1 rs31489 polymorphism is
associated with lung cancer risk: A meta-analysis. Tumour Biol.
35:5583–5588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneider MA, Christopoulos P, Muley T,
Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller
NS, Theis F, et al: AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five
specific mitosis-associated genes correlate with poor prognosis for
non-small cell lung cancer patients. Int J Oncol. 50:365–372. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sarajlić A, Filipović A, Janjić V, Coombes
RC and Pržulj N: The role of genes co-amplified with nicastrin in
breast invasive carcinoma. Breast Cancer Res Treat. 143:393–401.
2014. View Article : Google Scholar
|
|
26
|
Lombardo Y, Filipović A, Molyneux G,
Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yagüe E, Michel
L, et al: Nicastrin regulates breast cancer stem cell properties
and tumor growth in vitro and in vivo. Proc Natl Acad Sci USA.
109:16558–16563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sander JD and Joung JK: CRISPR-Cas systems
for editing, regulating and targeting genomes. Nat Biotechnol.
32:347–355. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Doudna JA and Charpentier E: Genome
editing. The new frontier of genome engineering with CRISPR-Cas9 .
Science. 346:12580962014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hua Y, Jia X, Sun M, Zheng L, Yin L, Zhang
L and Cai Z: Plasma membrane proteomic analysis of human
osteosarcoma and osteoblastic cells: Revealing NDRG1 as a marker
for osteosarcoma. Tumour Biol. 32:1013–1021. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qu Z, Gao F, Li L, Zhang Y, Jiang Y, Yu L,
Zhou Y, Zheng H, Tong W, Li G, et al: Label-free quantitative
proteomic analysis of differentially expressed membrane proteins of
pulmonary alveolar macrophages infected with highly pathogenic
porcine reproductive and respiratory syndrome virus and its
attenuated strain. Proteomics. 17:17001012017. View Article : Google Scholar
|
|
31
|
Zhang Z, Zhang L, Hua Y, Jia X, Li J, Hu
S, Peng X, Yang P, Sun M, Ma F, et al: Comparative proteomic
analysis of plasma membrane proteins between human osteosarcoma and
normal osteoblastic cell lines. BMC Cancer. 10:2062010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alzahrani F, Clattenburg L, Muruganandan
S, Bullock M, MacIsaac K, Wigerius M, Williams BA, Graham ME, Rigby
MH, Trites JR, et al: The hippo component YAP localizes in the
nucleus of human papilloma virus positive oropharyngeal squamous
cell carcinoma. J Otolaryngol Head Neck Surg. 46:152017. View Article : Google Scholar : PubMed/NCBI
|
